Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
199
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial

Elizabeth H. PhillipsCancer Research UK and University College London Cancer Trials Centre, London, UK;
,
Stephen DevereuxKing's College Hospital NHS Foundation Trust, London, UK;
,
John RadfordUniversity of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK;
,
Naheed MirHaematology Department, University Hospital Lewisham, London, UK;
,
Toyin AdedayoCancer Research UK and University College London Cancer Trials Centre, London, UK;
,
Laura Clifton-HadleyCancer Research UK and University College London Cancer Trials Centre, London, UK;
&
Rod JohnsonDepartment of Haematology, Leeds Cancer Centre, Leeds, UKCorrespondence[email protected]
 show all
Pages 2291-2294 | Received 17 Sep 2018, Accepted 23 Jan 2019, Published online: 18 Feb 2019

References

  • Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
  • Geissinger E, Bonzheim I, Roth S, et al. CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma. 2009;50:1010–1016.
  • Jiang LY, Yuan CM, Hubacheck J, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol. 2009;145:173–179.
  • Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726.
  • Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004;103:2920–2924.
  • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JCO. 1999;17:1244.
  • Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al. Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma. Ann Oncol. 2011;22:1595–1600.
  • d'Amore F, Silva MGd, Leppa S, et al. First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2011;118:4110–4110.
  • Kim JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60:129–134.
  • Gallamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007;110:2316–2323.
  • Buckstein R, Fraser G, Cheung M, et al. Alemtuzumab and CHOP chemotherapy for the treatment of aggressive histology peripheral T cell lymphomas: a multi-center phase I study. Clin Lymphoma Myeloma Leuk. 2016;16:18–28.
  • Trumper LH, Wulf G, Ziepert M, et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: final results of 116 patients treated in the international ACT-2 phase III trial. JCO. 2016;34:7500–7500.
  • d'Amore F, Leppä S, Silva MGd, et al. Final analysis of the front-line phase III randomized ACT-1 trial in younger patients with systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2018;132:998–998.
  • Montagna M, Montillo M, Avanzini MA, et al. Relationship between pharmacokinetic profile of subcutaneously administered alemtuzumab and clinical response in patients with chronic lymphocytic leukemia. Haematologica. 2011;96:932–936.
  • Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral T-cell lymphoma. Haematologica. 2007;92:566–567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.